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SHORT REVIEW
Recessive mechanisms of malignancy
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Summary It is increasingly recognised that recessive mutations play an important role in the pathogenesis of
many forms of malignancy. Some of the affected loci may prove to be recessively-activated proto-oncogenes,
but others are now known to be tumorigenic solely by virtue of their loss or inactivation and therefore form a
distinct and novel family of tumour genes. Preliminary evidence suggests that such genes are likely to be
functionally heterogeneous and to encode molecules involved in the inhibition of cellular proliferation and/or
the induction of differentiation. Their further study is likely to illuminate fundamental mechanisms of normal
cellular growth and differentiation as well as having important implications for the pathogenesis and
management of cancer.
Cancer is a genetic disease, a statement which reflects the
premise that mutations, stable structural alterations in cellu-
lar DNA, play a crucial role in the development of tumours.
The suggestion that malignancy is caused by alterations in
cellular genetic material is not new (Boveri, 1914) and
overwhelming evidence has now accrued in support of the
somatic mutation theory of cancer (Bishop, 1987): Both
chemical carcinogens and ionising radiation are mutagenic
and the biochemical basis for some of the resultant DNA
alterations have been described (Miller, 1978; Storer, 1982);
some diseases associated with an increased incidence of
cancer are characterised by defects in DNA repair mecha-
nisms (Cleaver, 1968; Paterson et al., 1976), and more
recently DNAse I encapsulated in liposomes has been shown
to be capable of inducing cellular transformation (Zajac-
Kaye & Tso, 1984).
In view of the complexity and vast size of the mammalian
genome (approximately 3 x 109 base pairs of DNA) it is not
surprising that the nature of the genetic targets for tumor-
igenic mutations remained completely unknown until seren-
dipity gave science a helping hand in the form of the rapidly
tumorigenic retroviruses. Members of this retroviral sub-
group were known to induce experimental tumours rapidly
in vivo and to transform cells in vitro, and the relative
simplicity of their genetic structure (approximately 104 base
pairs of DNA) made them attractive tools for the dissection
of malignancy. With the advent of molecular technology it
became apparent that they contain specific viral oncogenes
that are responsible for their malignant properties, and
furthermore and these viral genes are derived from, and
represent a subset of, host cellular genes (proto-oncogenes)
present in normal cell DNA (Bishop, 1981). It is now
thought that proto-oncogenes altered by mutational events
play an important role in many human tumours, a view that
is supported by three main lines of evidence:
(a) Certain tumour-specific chromosome translocations
appear to result in proto-oncogene activation. The t
(8, 14), t (2, 8) and t (8, 22) translocations associated
with Burkitt's lymphoma all seem to result in dysregu-
lation of c-myc expression (Cory, 1986). In CML the t
(9, 22) translocation fuses c-abl to a previously
unknown gene (bcr) thereby producing a chimaeric
gene the protein product of which has an altered
tyrosine kinase activity (Champlin and Golde, 1985).
(b) Amplification of several different proto-oncogenes has
been described in a variety of human tumours and
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tumour cell lines (Stark, 1986). Furthermore in neuro-
blastoma and breast cancer amplification of N-myc and
neu respectively correlates with tumour stage and
provides useful prognostic information (Seeger et al.,
1985; Slamon et al., 1987; Editorial, 1987).
(c) Proto-oncogenes of the ras family, activated by point
mutations, are found with varying frequencies in most
types of human tumours and can be detected by in
vitro transformation of NIH/3T3 cells (Der et al., 1982;
Parada et al., 1982; Santos et al., 1982; Hall et al.,
1983), in vivo tumorigenicity assays (Fasano et al.,
1984) or by direct biochemical methods (Bos et al.,
1987).
The evidence that cancer is associated with proto-
oncogene activation is also consistent with the concept of
cancer as a multistep process. Thus it has been demonstrated
that different activated proto-oncogenes can cooperate in the
production of both tumours (Kahn et al., 1986) and cell
transformation (Land et al., 1983). Moreover, analysis of the
structure and function of the molecules encoded by proto-
oncogenes has shown that many operate as components of
normal cellular growth regulatory pathways, as growth
factors, growth factor receptors or within the intra-cellular
post-receptor pathway (Editorial, 1986). Such studies have
provided dramatic insights into our understanding of the
molecular basis of both malignancy and also normal cellular
growth and differentiation.
However studies of activated proto-oncogenes tend to
provide a rather one-sided view of carcinogenic genetic
damage because they concentrate on tumorigenic mutations
that produce a functional gene product and which appear to
act in a dominant manner. Thus the introduction of an
activated proto-oncogene into certain normal cell lines by
DNA transfer techniques or as part of a retrovirus, results in
the acquisition of readily recognisable malignant characteris-
tics by the recipient cells. By contrast, genes that are ablated
by carcinogenic mutations would be much more difficult to
detect.
The idea that loss-of-function mutations may play a role
in the development of tumours is not new and was first
implied by studies of the tumorigenicity of cell hybrids
(Harris et al., 1969) together with Knudson's mathematical
analysis of retinoblastoma incidence (Knudson, 1971). Subse-
quently Ohno (1971) suggested that chromosome loss may
play an important role in tumorigenesis and two years later
Comings (1973) extended these ideas by postulating that
regulatory loci whose products control proto-oncogene
expression may act as targets for loss-of-function carcino-
genic mutations. Since these early prescient papers consider-
able evidence has accrued in favour or the concept that gene
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loss or inactivation plays a crucial role in the genesis of
some, and possibly most, tumours. Loss-of-function muta-
tions may promote the neoplastic growth of an affected cell
in either an indirect or a direct manner. The genetic defects
responsible for xeroderma pigmentosum, ataxia telangiecta-
sia and Bloom's syndrome probably fall into the former
category. These inherited conditions are associated with a
predisposition to a variety of cancers and are thought to
involve germ line inactivating mutations which facilitate
tumorigenesis by interfering with DNA repair processes, thus
enhancing the accumulation of somatic mutations (Lehman,
1982; Chan et al., 1987; Willis & Lindahl, 1987). It is
conceivable that somatically acquired mutations in DNA
repair genes also play a significant role in carcinogenesis and
this possibility is consistent with observations that ataxia
telangiectasia heterozygotes have an increased incidence of
cancer (Swift, 1982; Swift et al., 1987) and that some tumour
cells exhibit a reduced ability to repair DNA (Day et al.,
1980). However this review will concentrate on genes in
which loss-of-function mutations appear to play a direct role
in the neoplastic process. Evidence for their existence stems
from studies of two different phenomena: the suppression of
malignancy in cell hybrids and the loss or inactivation of
specific genes in a wide variety of tumours.
Tumour suppressor genes
It had been realised for many years that fusion of tumorige-
nic malignant cells to non-malignant cells usually produces
non-tumorigenic cell hybrids which subsequently segregate
tumorigenic hybrids (Harris et al., 1969; Klein et al., 1971).
Chromosome analysis reveals that the tumorigenic segregants
have lost several chromosomes originally present in the non-
tumorigenic hybrid cells. These results have now been con-
firmed by extensive studies of rodent and human intraspecies
hybrids (Miller & Miller, 1983; Sager, 1985; Stanbridge,
1987) together with rodent x human interspecies hybrids
(Klinger, 1982). The simplest interpretation of these obser-
vations is that non-malignant cells contain one or more
tumour suppressor genes that are capable of repressing
aspects of the malignant phenotype, and which are presum-
ably inactive in, or absent from, malignant cells. Cell hybrids
that result from the fusion of appropriate malignant and
non-malignant cells are therefore initially non-malignant but
may re-express malignant characteristics following the loss of
chromosomes carrying tumour suppressor genes.
As a first step towards identifying such genes, numerous
investigators have compared the karyotypes of malignant
and non-malignant hybrids in attempts to identify specific
chromosomes the loss of which is associated with malig-
nancy. Studies of intraspecies rodent cell hybrids have been
hampered both by the difficulty of distinguishing the paren-
tal origin of chromosomes in the hybrids, and by the
random and often rapid loss of chromosomes from the
hybrids. As a result several groups have examined human
x rodent cell hybrids because chromosome loss is not
random (human chromosomes are preferentially lost) and
because human and rodent chromosomes can be dis-
tinguished. However the rapidity with which human chromo-
somes are lost still provides a serious obstacle since re-
expression of malignancy is usually associated with the loss
of multiple chromosomes. It is therefore not surprising that
both of these approaches have usually failed to identify
specific suppressor chromosomes although there are a few
notable exceptions to this (Klinger, 1982; Evans et al., 1982;
Stoler & Bouck, 1985).
Perhaps the most penetrating insights have come from the
use of intraspecies human cell hybrids which have been
found to exhibit a very stable karyotype. Extensive studies
by both Stanbridge and his co-workers (Srivatsan et al.,
1986) and Klinger with his colleagues (Kaelbling & Klinger,
1986) have implicated chromosome 11 from normal human
fibroblasts in the suppression of tumorigenicity of HeLa
cervical carcinoma cells. These results have been confirmed
by an elegant series ofexperiments in which the technique of
microcell fusion was used to introduce a single fibroblast
chromosome 11 into HeLa cells and thereby suppress tumor-
igenicity of the recipient cells (Saxon et al., 1986). By
contrast fibroblast chromosome 1 has been reported to
suppress tumorigenicity of human HT 1080 fibrosarcoma
cells (Benedict et al., 1984). This suggests that different
tumour suppressor loci may be defective in different tumour
types, a possibility that is supported by the observation that
HeLa x HT 1080 cell hybrids are non-tumorigenic (Weissman
& Stanbridge, 1983). Stanbridge's group have also pointed
out that non-tumorigenic HeLa x fibroblast hybrids remain
transformed in vitro (Stanbridge et al., 1982), a finding which
accords well with the concept that malignancy is a multistep
process (Klein & Klein, 1985).
Gene loss or inactivation in tumours
Recessive mutations at specific loci are implicated in the
development of a variety of human and animal tumours
(Knudson, 1985). In Drosophila recessive mutations at more
than 20 different loci can result in a variety of tissue-specific
tumours (Gateff, 1978; Gatef, 1982) and, further up the
phylogenetic scale, genetic studies of Xiphophorus, a genus
of Central American fish, suggest that loss or inactivation of
regulatory genes allows a proto-oncogene to promote subse-
quent tumour formation (Anders, 1983; Anders et al., 1985).
The affected genes have been referred to as anti-oncogenes
(Green & Wyke, 1985; Knudson, 1985) although this term
should not be taken to necessarily imply a direct interaction
with oncogenes.
Retinoblastoma and Wilms' tumour are the best studied
human malignancies involving recessive mechanisms.
Knudson (1971) originally suggested that retinoblastomas
result from two sequential mutations and it has subsequently
become evident that these affect both alleles of a particular
gene; in familial cases the first mutation is inherited, whereas
both mutations are somatic in sporadic cases. This explains
the apparent paradox whereby predisposition to the tumour
may be inherited as an autosomal dominant trait at the level
of the whole organism, whilst at the cellular level the
neoplastic defect is recessive. This theory has been extended
by cytogenetic (Francke, 1976) and linkage (Sparkes et al.,
1980) studies that have mapped the retinoblastoma locus
(Rbl) to band q14 on chromosome 13. Restriction fragment
polymorphism (RFLP) analysis has identified mechanisms by
which the wild type allele is eliminated in tumours (Cavanee
et al., 1983): most cases appear to involve mitotic non-
disjunction or recombination with the resultant loss of all or
part of the chromosome carrying the normal allele (Figure 1,
i-iv). Cavenee and collaborators have also shown that the
tumorigenic effect of recessive mutations at the Rbl locus is
not confined to the retina. Survivors of the heritable form of
retinoblastoma have a greatly increased chance of developing
osteosarcomas which also involve recessive changes at the
Rbl locus, and similar alterations occur during the develop-
ment of sporadic osteosarcomas in patients with no history
of the eye tumour (Hansen et al., 1985).
Wilms' tumour or nephroblastoma also occurs in heritable
and sporadic forms and familial cases may be associated
with aniridia, genito-urinary abnormalities and mental retar-
dation. Cytogenetic studies of individuals with the heritable
form of the disease have revealed an association with
constitutional deletions involving band p13 of chromosome
11 (Riccardi et al., 1978; Francke et al., 1979) and similar
abnormalities are seen in some tumours from patients with
no family history of the disease (Slater, 1986). In tumours
with an apparently normal karyotype, and in cases where no
karyotypic data are available, RFLP analysis has confirmed
the presence of deletions involving the short arm of chromo-
some 11 (Fearon et al., 1984; Koufos et al., 1984; Orkin et
al., 1984) and similar alterations have been reported to occurRECESSIVE MECHANISMS OF MALIGNANCY 117
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Figure 1 The use of restriction fragment length polymorphism
(RFLP) analysis to study mechanisms responsible for loss/
inactivation of the normal RB1 allele in retinobfastoma (Cavenee
et al., 1983). The cells of a patient who inherits one chromosome
13 carrying a mutant Rbl gene (rb) will also contain a normal
chromosome 13 carrying a wild type Rbl gene (RB). The figure
demonstrates a case in which the affected individual is hetero-
zygous for each of 3 pairs of RFLPs (al/a2, bl/b2, and cl/c2)
flanking the Rbl locus on the long arm of chromosome 13.
During the development of a retinoblastoma the normal Rbl
gene may be lost/inactivated by a number of different molecular
mechanisms, most of which can be distinguished by the RFLP
pattern present in the tumour: (i) chromosomal non-disjunction,
(ii) non-disjunction followed by duplication of mutant chromo-
some, (iii) mitotic recombination, (iv) point mutation or gene
conversion.
during the development of other embryonal tumours
(Koufos et al., 1985). These data are all consistent with the
presence of a recessive tumour gene at llpl3. However a
simple 'two hit' hypothesis would suggest that maternal and
paternal alleles of such a gene would have an equal prob-
ability of being affected by each hit. One hint that the
mechanisms may not be quite so simple comes from the
finding that the maternal chromosome 11 is lost much more
frequently than its paternal homologue in sporadic Wilms'
tumours (Schroeder et al., 1987). The explanation for this
observation is unclear but may involve differential sensitivity
of maternal and paternal gametes to mutations at llpl3 or
the presence of a linked transforming gene that is differen-
tially expressed by maternal and paternal copies of chromo-
some 11 (Wilkins, 1988).
Although both retinoblastoma and Wilms' tumour are
rare malignancies, evidence is emerging that similar mecha-
nisms are involved in colon cancer, a much more prevalent
tumour. Once again vital clues to the location of the gene
involved came from studies of a familial form of the disease,
in this case familial adenomatous polyposis (FAP) in which
one or more polyps almost invariably progresses to invasive
carcinoma. Following a single case report of a patient with a
constitutional deletion of Sq associated with adenomatous
polyposis, RFLP analysis of FAP pedigrees has localised the
FAP gene to 5q 21-22 (Bodmer et al., 1987). Having
identified this region as being of potential importance in
colonic malignancy, a minisatellite probe specific for Sq was
used to demonstrate loss of heterozygosity in the terminal
part of Sq in 20% of spontaneous colon cancers (Solomon et
al., 1987).
These paradigms have stimulated much interest and there
is now a rapidly growing list of human tumours associated
with genetic loss at specific chromosomal locations (Table I).
In the light of these observations it seems probable that gene
loss/inactivation will play an important role in a very wide
variety of human tumours. But what of the relationship
between the genes lost or inactivated in tumours and the
tumour suppressor genes detected in vitro? It is highly likely
that they are related and preliminary evidence for this
contention has recently been obtained: Stanbridge and his
co-workers have shown that tumorigenicity of Wilms'
tumour cells can be suppressed by the introduction of a
single human chromosome 11 (Weissman et al., 1987),
although further experiments are needed to show that it is
indeed the p13 region and not some other linked locus that
mediates suppression.
Relationship to proto-oncogenes
The evidence surveyed above suggests that various aspects of
the malignant phenotype may result from loss or inactivation
of specific cellular genes. However these observations need to
be reconciled with the mass of evidence that proto-oncogene
activation plays a central role in malignancy.
Table I Examples of genetic loss associated with human tumours
Chromosomal
Tumour site involved Reference
Retinoblastoma 13ql4 Francke, 1976; Knudson et al., 1976;
Osteosarcoma Hansen et al., 1985
Wilms' tumour llpl3 Fearon et al., 1984; Koufos et al., 1984;
Hepatoblastoma Orkin et al., 1984; Koufos et al., 1985
Rhabdomyosarcoma
Bladder carcinoma lip Atkin & Baker, 1984; Fearon et al., 1985
Bilateral acoustic neuroma 22 Seizinger, et al., 1986; Seizinger et al.,
1987a
Meningioma 22 Seizinger et al., 1987b
Myelodysplasia and acute
myeloid leukaemia 5p and 7 Yunis, 1983
'Lymphomatous ALL' 9p (21-22) Chilcote et al., 1985
Follicular non-Hodgkin's lymphoma 6p and 13q32 Yunis et al., 1987
Small cell lung cancer 3p (14-23) Whang-Peng et al., 1982;
Brauch et al., 1987
Renal cell carcinoma 3p Zbar et al., 1987; Kovacs et al., 1988
Multiple endocrine neoplasia syndromes:
type 1 11 Larsson et al., 1988
type 2 1 Mathew et al., 1987
Colon cancer Sq Solomon et al., 1987
17 Fearon et al., 1987
Breast cancer 11 Ali et al., 1987
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As described above the suppression of HeLa cell tumorige-
nicity by human fibroblasts has been studied in great detail,
but unfortunately virtually nothing is known about the
contribution that activated proto-oncogenes make to the
malignant properties of HeLa cells. The interaction of
tumour suppressor genes with proto-oncogenes has therefore
been addressed by studying the suppression of malignant
cells known to contain an activated proto-oncogene. Studies
of the HT 1080 human fibrosarcoma cell line and the EJ
human bladder cell line, which contain an activated N-ras
and Ha-ras gene respectively (Hall et al., 1983; Parada et al.,
1982) have produced three important observations:
1. The effect of activated ras genes may be suppressed at a
post-translational level, perhaps by interference with the
ras protein or its substrate. Hence suppression of EJ
cell tumorigenicity by fusion with human fibroblasts is
not accompanied by any alteration in the level of the
protein product of the activated ras gene (Geiser et al.,
1986).
2. The phenotype of cell hybrids may reflect the net effect
of two opposing influences; the number of suppressor
chromosomes relative to the number of chromosomes
carrying activated proto-oncogenes. Thus diploid
human fibroblasts can suppress the tumorigenicity of
near-diploid HT 1080 cells but not that of near-
tetraploid HT 1080 variants (Benedict et al., 1984).
3. Suppression of HT 1080 tumorigenicity is probably
mediated by chromosome 1, the very chromosome to
which N-ras has been mapped (Benedict et al., 1984).
Chromosome 1 may therefore carry a tumour suppres-
sor gene in addition to N-ras but an alternative possibi-
lity is that the unaltered N-ras allele itself is capable of
regulating its activated counterpart.
Several investigators have utilised a different approach and
studied suppression of rodent cells transformed by the
introduction of an activated proto-oncogene. These experi-
mental systems have the advantage that the activated proto-
oncogenes are known to be causally related to the phenotype
being studied and they have revealed two different molecular
mechanisms of suppression. Both transformation and tumor-
igenicity of Ha-ras transformed cells are suppressed by
fusion to untransformed cells, but suppressed hybrids thus
obtained continue to express the activated Ha-ras gene, the
effect of which is presumably inhibited at a post-
translational level (Craig & Sager, 1985; Griegel et al., 1986).
A different mechanism has been revealed by analysis of
untransformed hybrids resulting from the fusion of Rous
sarcoma virus-transformed rat fibroblasts (containing the
v-src oncogene) to untransformed rodent cell lines. In this
system suppression operates by repression of proviral trans-
cription and it has also been shown that the susceptibility of
a provirus to suppression is greatly influenced by its cellular
integration site (Dyson et al., 1982). Suppression of RSV-
induced transformation may therefore be mediated by a
family of negative regulatory genes that control transcription
within specific regions of the cellular genome (Green &
Wyke, 1985; Wyke & Green, 1986). Moreover some
members of such a family of regulatory genes might be
expected to act as targets for carcinogenic recessive muta-
tions (Comings, 1973).
A third strategy is to look for proto-oncogene expression
in tumours known to involve loss or inactivation of specific
loci but the results are difficult to interpret. Thus retino-
blastomas express high levels of N-myc and as a result it has
been suggested that- one function of the Rbl gene is to
repress N-myc expression (Lee et al., 1984). This now seems
unlikely since the level of N-myc expression in retinoblasto-
mas, although significantly higher than that found in fibro-
blasts or normal adult retina, is similar to the level found in
normal foetal retina and, furthermore, osteosarcomas that
involve inactivation of the Rbl locus do not express high
levels of N-myc (Squire et al., 1986).
It is apparent that in most instances genes which are
tumorigenic by virtue of loss of their function represent a
novel family of tumour genes quite distinct from proto-
oncogenes. However the issue is complicated by recent
evidence which suggests that some proto-oncogenes may be
activated by recessive mutations. Thus several tumours
known to contain an activated ras gene have deleted the
normal ras allele (Santos et al., 1982; Feinberg et al., 1983;
Guerrero et al., 1985); studies of mouse skin carcinogenesis
have shown that whereas papillomas contain both an acti-
vated and a normal Ha-ras allele, progression to invasive
carcinoma may be accompanied by loss of the normal allele
(Quintanilla et al., 1986); and the chromosome carrying an
unaltered N-ras allele can suppress tumorigenicity of HT
1080 cells containing an activated N-ras gene (vide supra).
These data emphasise that genes which are tumorigenic in a
recessive mode may fall into two categories: those that are
neoplastic solely by virtue of net loss of their function and
proto-oncogenes which exert a neoplastic effect when loss of
one allele unmasks an activating mutation in its homologue.
Cloning recessive tumour genes
Approximately 40 proto-oncogenes have already been cloned
and the relative ease with which this has been achieved
reflects several factors. Many proto-oncogenes were orig-
inally identified as components of tumorigenic retroviruses
thus greatly simplifying their isolation. In addition certain
activated proto-oncogenes can be detected by their ability to
transform cells in vitro or to render them tumorigenic. The
ability to both recognise and select for cells that have
incorporated an activated proto-oncogene has been used as
the basis for the isolation of several different proto-
oncogenes (Der et al., 1982; Hall et al., 1983; Fasano et al.,
1984).
The isolation of genes that are absent or inactivated in
tumours is inherently more difficult. However in a major
recent advance two groups have isolated what appears to be
a cDNA clone of the retinoblastoma gene by 'walking' along
chromosome 13 from an anonymous sequence closely linked
to the Rbl locus (Friend et al., 1986; Lee et al., 1987a).
When used as a probe in Northern blots it detects a discrete
transcript in normal retinal cells and in a variety of tumour
cell lines, but not in retinoblastoma cells. Furthermore in
Southern blots it reveals rearrangements and deletions in a
minority of retinoblastomas and associated second tumours.
That only a minority of tumours have abnormal restriction
fragments is not surprising since many small structural
aberrations capable of inactivating the gene will not be
detected by Southern blotting. The Wilms' tumour locus is
also being studied intensively (van Heyningen et al., 1985;
Porteous et al., 1987) and it is anticipated that this will be
characterised in the near future.
The isolation of genes involved in the hybrid suppression
of malignancy is in some ways even more challenging since
there are no chromosomal deletions that can be used to
localise the gene and act as a starting point for cloning
quests. At least two strategies are currently in use. The first
involves the transfer of DNA from normal cells into trans-
formed recipients; cells that have taken up a tumour sup-
pressor gene can be isolated by selecting for recipient cells
with a normal phenotype, and the introduced gene even-
tually cloned after two or more rounds of transfection. This
approach is hampered by the technical difficulty of separat-
ing slow-growing and contact-inhibited untransformed cells
from a population of transformed cells. However Schaefer et
al. (1988) have overcome this problem by using ouabain to
select for untransformed cells and they have recently
reported the isolation of a putative human suppressor gene
capable of partially reversing the transformed phenotype of
ras-transfected rat fibroblasts. An alternative approach is
based on the premise that inactivation of a tumour suppres-
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transformation of a previously untransformed cell. This
'insertional mutagenesis' approach is particularly powerful
since the transformed clone would be easy to isolate and the
integrated provirus would provide a molecular tag for clon-
ing the tumour suppressor gene. For this approach to be
feasible the target gene must be present as a single functional
copy, a situation that obtains in some cell hybrids that have
retained only a single copy of the suppressor chromosome.
Functions
Proto-oncogenes are structurally and functionally hetero-
genous and it is likely that recessively acting tumour genes
will prove equally diverse. Indeed evidence is accumulating
that, whereas proto-oncogenes apparently function in posit-
ive growth regulatory pathways, genes that are carcinogenic
when their function is reduced or abolished will prove to be
involved at various levels in comparable negative regulatory
pathways. Several points are relevant to this hypothesis:
1. Studies of the suppression of HeLa cell tumorigenicity
have shown that both tumorigenic hybrids and HeLa
cells themselves rapidly produce undifferentiated
tumours after injection into nude mice, whereas non-
tumorigenic hybrids undergo terminal differentiation.
Moreover the pathway of differentiation adopted by
hybrid cells is dictated by the normal diploid parental
cell. Thus fibroblast x Hela cell hybrids become fibro-
blastoid (Stanbridge et al., 1982) whereas keratino-
cytexHeLa cell hybrids differentiate into keratinising
epithelium (Peehl & Stanbridge, 1982). These results
are consistent with the possibility that, in this experi-
mental system, tumour suppressor genes encode
molecules which allow hybrid cells to respond to
differentiation inducing signals in vivo.
2. The recent cloning of two recessive tumour genes
(Mechler et al., 1985; Friend et al., 1986; Lee et al.,
1987a) has allowed direct analysis of their protein
products. Mutation of the drosophilia 1(2) gl gene is
implicated in larval neuroblastomas and imaginal disc
tumours. Its protein product localises to the cell mem-
brane and intercellular matrix and its expression during
embryonic and larval development correlates with cess-
ation of cellular proliferation suggesting that it may
mediate proliferation arrest (Klambt & Schmidt, 1986).
By contrast the retinoblastoma gene product is a
nuclear phosphoprotein with DNA binding activity and
so may act to regulate other cellular genes (Lee et al.,
1987b).
3. An increasing number of peptides are known to exhibit
differentiation-inducing or growth-inhibiting effects
(Roberts et al., 1985; Marx, 1986; Beutler & Cerani,
1987; Gearing et al., 1987). This hypothesis predicts
that the genes encoding such inhibitory factors and
their cellular receptors would be prime targets for
recessive carcinogenic mutations.
Clinical applications
It is not premature to consider the potential implications of
these insights. RFLP analysis has already been used as an
approach to ante-natal diagnosis in pedigrees at risk for
retinoblastoma (Cavenee et al., 1986; Wiggs et al., 1988) and
the availability of cloned probes for the locus should greatly
increase predictive accuracy. Both diagnostic and prognostic
information is also likely to ensue from the characterisation
of other genes that are tumorigenic by virtue of their
inactivation.
Possible therapeutic applications are tantalizing but dis-
tant. Antibodies which stimulate cellular receptors for inhibi-
tory factors or the inhibitory factors themselves may prove
clinically useful. It will also soon be possible to construct
retroviral vectors containing genes capable of repressing the
malignant phenotype and perhaps it will even prove feasible
to suppress various aspects of malignancy in vivo by use of
such vectors. As with all anti-tumour therapy, the effects are
unlikely to be completely specific for tumour cells, but the
potential importance of such novel therapeutic modalities
remains considerable.
I am indebted to Dr J.A. Wyke, Dr C.J. Poole, Professor A. Jacobs
and Dr D.P. Bentley for helpful comments on this manuscript and
to Miss Nikki Pinchen and Mrs Marion Watkins for their secretarial
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